 RedHill Biopharma Ltds NASDAQ: RDHL opaganib ABC294640, an oral drug candidate for hospitalized COVID-19 patients, demonstrated potent in vitro efficacy against the omicron variant while maintaining host cell viability. The Company says that based on the new and. 